Among the 194 patients with relapsed or refractory B-ALL treated with the co-administration of CD19- and CD22-CAR-T cells, the median age was 7.6 years (range 0.8–19.6 years). The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.